Hexal AG Report issue

For profit Phase 3 Phase 4
Founded: Holzkirchen Germany (1986)
Status: Acquired by Novartis (2005)

Organization Overview

First Clinical Trial
2004
NCT00666835
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Hexal AG

Active Ingredients

Drugs in Phase 4 Trials (1)

epoetin (Epogen) (5 trials)

Drugs in Phase 3 Trials (4)

adalimumab (humira) (2 trials)

denosumab (prolia) (1 trial)

etanercept (enbrel) (1 trial)

rituximab (rituxan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Kidney Diseases (Phase 4)

Osteoporosis (Phase 3)

Psoriasis (Phase 3)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 5